UPB
Upstream Bio, Inc.
Key Financials
Net Income
$-143443000
↓ 128.4%
Operating Income
$-160361000
↓ 106.2%
EPS (Diluted)
$-2.66
↑ 52.3%
Total Assets
$353.8M
↓ 26.6%
Revenue
$2.9M
↑ 20.4%
Total Liabilities
$14.0M
↑ 18.0%
Shareholders' Equity
$339.8M
↓ 27.7%
Cash & Equivalents
$101.6M
↓ 68.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/12/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| SCHEDULE 13G | 7/30/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | UPB |
| Company Name | Upstream Bio, Inc. |
| CIK | 2022626 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-208-2466 |